Pharmacotherapy of pediatric and adolescent HIV infection

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 469-484

  Schuval, Susan J ^a,b  

^a Northwell Health   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral; HAART; HIV; Pediatric guidelines

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETHINYLESTRADIOL; FOSAMPRENAVIR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RIFABUTIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADOLESCENT DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; ASTHENIA; ATRIOVENTRICULAR BLOCK; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BODY FAT DISTRIBUTION; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHILDHOOD DISEASE; CHRONIC LIVER DISEASE; CONSULTATION; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ERYTHEMA MULTIFORME; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPERPIGMENTATION; HYPERURICEMIA; INJECTION SITE CELLULITIS; INJECTION SITE REACTION; INSOMNIA; JAUNDICE; LEUKOPENIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER TOXICITY; MALAISE; MEDICAL SPECIALIST; MENTAL DISEASE; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PR INTERVAL; PRACTICE GUIDELINE; RASH; RETINA; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SURVIVAL; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 77949483228     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s4594     Document Type: Review

References (58)

1. Scarlatti G. Paediatric HIV infection. Lancet. 1996;349:863-868.
2. Vella S, Floridia M. Antiviral Therapy. In: Cohen and Powderly, editors. Infectious Diseases, New York: Mosby; 2004. Chapter 139.
3. Working Group on Antiretroviral Therapy and the Medical Management of HIV-Infected Children. February, 2009. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Accessed March 31, 2009. Available from: http://AIDSinfo.nih.gov.contentfiles/PediatricGuidelines.pdf.
4. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 2005. Accessed March 31, 2009. Available from: http://AIDSinfo.nih.gov.
5. 2008 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. Accessed March 31, 2009. Available from: http://AIDSinfo.nih.gov.
6. Schlecht HP, Schellhorn S. Dezube BJ, Jacobson JM. New approaches in the treatment of HIV/AIDS- Focus on maraviroc and other CCR5 antagonists. Ther Clin Risk Manag. 2008;4:473-485.
7. Patel K, Hernan MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008: 46(11):1751-1760.
8. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immunovirological response of African HIV-1 infected children to highly active antiretroviral therapy regimens. Aids. 2006;20(18):2315-2319.
9. Rudin C, Burri M, Shen Y, Rode R, Nadal D. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J. 2008;27(5):431-437.
10. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodefi-ciency virus type 1 infection. N Engl J Med. 1997;336(19):1343-1349.
11. McKinney RE, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. 1998;133(4):500-508.
12. Van Dyke RB, Wang L, Williams PL, et al. Toxicities associated with dual nucleoside reverse transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599-1608.
13. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/ abacavir beyond 5 years in children. Aids. 2007;21(8):947-955.
14. Saez-Llorens X, Violari A, Ndiweni D, et al. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected subjects. Pediatrics. 2008;121(4):e827-e835.
15. Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses. 2000;16(5):415-421.
16. McKinney RE Jr, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV- infected, therapy-naïve children and adolescents. Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics. 2007;120(2): e146-e23.
17. Cross SJ, Rodman FH, Lindsey JC, et al. Abacavir and metabolite pharmacokinetics in HIV-1 infected children and adolescents. J Acquir Immune Defic Syndr. 2009;51(1):54-59.
18. Saez-Llorens X, Nelson RP, Emmanuel P, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107(1)e4.
19. Mallal S, Phillips E, Carosi G, et al. HLA B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:2514-2516.
20. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118(3):e711-e718.
21. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J. 2009;28(3):204-209.
22. King JR, Acosta EP, Yogev R, et al. Steady state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2009;28(2):159-161.
23. Wintergerst U, Hoffman F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemotherapy. 2008;61(6): 1336-1339.
24. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy waith efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children with human immunodeficiency virus infection type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341(25):1874-1881.
25. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonvir in HIV-1 infected children. Antivir Ther. 2004;9(2):297-299.
26. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur J Med Res. 2005;10(12):503-508.
27. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1 infected children. Aids. 2003;17(11):1639-1647.
28. Luzuriaga K, McManus M, Mofenson L, et al. A Trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med. 2004;350(24):2471-2480.
29. Baylor M, Ayime O, Truffa M, et al. Hepatotoxicity associated with nevirapine use in HIV-infected children. Boston, MA: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005. Abstract 776.
30. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2(2):93-102.
31. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Accessed March 24, 2009. Available from: http://AIDSinfo.nih.gov/contentfiles/ AdultandadolescentGL.pdf.
32. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522-1528.
33. Larru B, Resino S, Bellon JM, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother. 2008:61(1):183-190.
34. Jankelevich S, Mueller BU, Mackall CL, et al. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis. 2001;183:1116-1120.
35. Saez-Llorens Xn, Violari A, Deetz C, et al. Forty-eight week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22(3):216-223.
36. Scherpier HJ, Bekker V, van Leth F, et al. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics. 2006;117(3):e528-e536.
37. Riordan A, Bugembe T. Update on antiretroviral therapy. Arch Dis Child. 2009;94:70-74.
38. Resino S, Larru B, Maria Bellon J, et al. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up: long-term responses to nelfinavir. BMC Infect Dis. 2006;11(6):107.
39. Cunningham D, Freedman A, Read S, et al. Safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year old pediatric subjects (Interim data, Study APV29005). Los Angeles, CA: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007. Abstract 718.
40. Lalezari J, Henry K, O'Hearn M, et al; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South /America. N Engl J Med. 2003;348:(22):2175-2185.
41. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2003;348(22):2228-2238.
42. Gulick RM, Lalezari, J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 Infection. N Engl J Med. 2008;359(14)1429-1441.
43. Hicks C, Gulick RM. Raltegravir: The first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48(7):931-939.
44. Brichard B, Van der Linden D. Clinical practice treatment of HIV infection in children. Eur J Pediatr. 2009;168(4)387-392.
45. Fulco PP, McNicholl IR. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy. 2009;29(3):281-294.
46. Pan C, Lu H, Qi Z, Jiang S. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. Aids. 2009;23(5):639-641.
47. Clay PG. Advances in human immunodeficiency virus therapeutics. Ann Pharmacother. 2006;40(4):704-709.
48. Thakkar N, Pirrone V, Passic S, et al. Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother. 2009;53(2):631-638.
49. Goetghbuer T, Haelterman E, Le Chenadec J, et al. Effect of early antiretroviral therapy on the risk of AIDS/Death in HIV-infected infants. AIDS 2009;23(5):597-604.
50. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age, 1994 (No. RR-12).p. 1-10.
51. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1 infected children. Aids. 2006;20(9):1289-1294.
52. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine, and didanosine. Aids. 2003;17(14):2045-2053.
53. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. 2002;359(9308):733-740.
54. Kline MW, van Dyke RB, Lindsey J, et al. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group Protocol 327 Team. Pediatrics. 1999;103(5):e62.
55. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med. 1997;336(24):1704-1712.
56. Deeks SG. Antiretroviral treatment of HIV infected adults. BMJ. 2006;332:1489-1503.
57. International AIDS Society-USA (IAS-USA). HIV drug resistance mutations. 2009. Accessed on February 10, 2009. Available from: http://iasusa.org/ resistance-mutations/index.html.
58. Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother. 2004;38(11):1924-1934.